Modern Trends of Radiotherapy Cancer Oral Cavity

Growth of frequency of squamous cell cancer of oropharynx and dominance of locally-spread forms of a tumor at 60 % with the early infiltrative growth and metastasis in regional lymph nodes reduce results of treatment to 40 %. The combination in a uniform course of treatment of operation, radiation therapy and chemotherapy doesn’t exclude risk the lokoregional of a recurrence at 30–60 % and at 18 % – isolated metastases. At patients at the age of 50 years with cancer of oropharynx 5 years treatment doesn’t exceed 40 %. At the same time switching on in programs of radiation and combined treatment with chemotherapy (CT) increases effectiveness of traditional methods to 69 %. New technologies of conformal radiation therapy (CRT); HDR brachytherapy with the radio modifying agents and PHT, including target drag – are implemented everywhere in case cancer of oropharynx. However CRT 66–70 Gr provides local control in case of 5–10 years’ observation only at 57 %; lokoregion – 50 % with the overall (OS) survival – 47 % and 35 %, respectively. There are data on detection of mutations in EGFR gene in case of malignant diseases of an oral cavity and throat. Directional application the target drag – EGFR blockers, for example a cetuximab (erbitux) in the first line of therapy of planocellular cancer of the head and neck increases survival indices. On the other hand, the raised expression of a gene of EGFR can correlate with progressing of a disease and the poor results. The aim: to provide new technologies of CRT with brachytherapy 192Ir and chemotherapy of 30 patients with cancer of cancer of oropharynx with assessment of presence of retrospectively probed mutation at EGFR gene. Results of CRT and HDR brachytherapy depended on tumor localization in oral cavity, a stage and prevalence of process, prognostic factors and treatment. CRT improved results of multimodal treatment and quality life of patients: the OS is reached at 100 % of patients with cancer of a lip; 66,7 % of patients with cancer of tongue and 75 % of cancer mouth bottom. EGFRvIII weren’t revealed in one of analysed samples of tumor. The positive effect from target therapy erbitux wasn’t registered at one of two treated patients without mutations of EGFR.

1. Korytova L.I., Sokurenko V.P., Maslennikova А.V. Current trends in therapy of locally advanced oral and oropharyngeal cancers. Spb; 2011, 110 p. [in Russian]

2. Romanov I.S., Alieva S.B. Evolution of using chemotherapy for squamous cell oral cavity carcinoma. Siberian Journal of Oncology. 2010; 3: 77–78. [in Russian]

3. Choynzonov E.Л., Startseva Zh.А., Mukhamedov М.R., Spivakova I.О., Gribov О.V., Kulbakin D.Е. Local hyperthermia in combined modality treatment of patients with laryngeal and hypopharyngeal cancers. Siberian Journal of Oncology. 2014; 5: 5–9. [in Russian]

4. Alieva S.B., Tkachev S.I., Zaderenko I.А., Romanov I.S. Chemoradiotherapy options for patients with locally advanced squamous cell pharyngeal carcinoma. Head and neck tumors. 2011; № 1: 26–31. [in Russian]

5. Cancer incidence in Russia and the CIS in 2012 / Ed. by М.I. Davydov, Е.М. Axel. М.; 2014, 226 p. [in Russian]

6. Worden F.P., Urba S.G., Bradford C. Induction chemotherapy to select for concomitant chemoradiation as organ preservation for patients with advanced squamous carcinoma of the oral cavity/oropharynx. ASCO. 2002; P. 952.

7. Brzhezovsky V.Zh., Lyubaev V.L., Khasanov R.А. Choice of treatment strategy for squamous cell oral cavity and oropharyngeal carcinomas. Siberian Journal of Oncology. 2010; 3: 58–59. [in Russian]

8. Zharkov О.А., Fedotenko S.P., Alieva S.B. Surgical treatment of patients with oral cavity cancer after previously performed radiation therapy. Siberian Journal of Oncology. 2010; 3: 63–64. [in Russian]

9. Kropotov М.А., Epikhina А.V. Surgical aspects of oripgaryngeal cancer. Head and Neck Tumors. 2011; 2: 5–14. [in Russian]

10. Reshetov I.V., Kravtsov S.А. Microsurgical reconstruction of the tongue in cancer patients. Oncosurgery. 2010. Suppl. 1: 178. [in Russian]

11. Titova V.A., Kharchenko N.V., Petrovsky V.Y., Kreynina Ju.M., Dykhno A.Y. Photodynamic therapy and laser interstitial thermotherapy in organ-preserve multimodal treatment of primary and recurrent oral cancer. Intern. J. Brachytherapy. 2008; 7 (2): 158.

12. Tsyb А.F., Mardynsky Yu.S., Gulidov I.А. Current state of radiation therapy for cancer. Therapeutic radiology: Manual for physicians. М.; 2010, P. 7–12. [in Russian]

13. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for squamous-sell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9; 354 (6): 567–78.

14. Chen W.C., Hwang T.Z., Wang W.H., Lu C.H., Chen C.C., Chen C.M., Weng H.H., Lai C.H., Chen M.F. Comparison between conventional and intensity-modulated post- operative radiotherapy for stage III and IV oral cavity cancer in terms of treatment results and toxicity. Oral Oncol. 2009 Jun; 45 (6): 505–10. doi: 10.1016/j.oraloncology.2008.07.002.

15. Hitt R., Martin P., Hidalgo M. Cetuximab in squamous carcinoma of head and neck. Future Oncol. 2006. Vol. 2, № 4: 449–457.

16. Johnson K. Brachytherapy Boost an Opinion for Base of Tongue Cancer. www/medscape medical news/com.-2013/803037.

17. Lindholm P., Valavaara R., Aitasalo K., Kulmala J., Laine J., Elomaa L., Sillanmäki L., Minn H., Grénman R. Preoperative hyperfractionated accelerated radiotherapy and radical surgery in advanced head and neck cancer: a prospective phase II study. Radiother Oncol. 2006 Feb; 78 (2): 146–51.

18. Setton J., Caria N., Romanyshyn J., Koutcher L., Wolden S.L., Zelefsky M.J., Rowan N., Sherman E.J., Fury M.G., Pfister D.G., Wong R.J., Shah J.P., Kraus D.H., Shi W., Zhang Z., Schupak K.D., Gelblum D.Y., Rao S.D., Lee N.Y. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82 (1): 291–8. doi: 10.1016/j.ijrobp.2010.10.041.

19. Boiko А.V., Bolotina L.V., Chernichenko А.V. The first experience in treating oropharyngeal cancer with cetuximab/cisplatin combined with radiotherapy. Modern oncology. 2010; 2: 26–31. [in Russian]

20. Gevorkov А.R., Boiko А.V., Chernichenko А.V. Targeted modification in radiation therapy for squamous cell oropharyngeal carcinoma. Vestnik RNCRR. 2012; 2 (3): 171. [in Russian]

21. van den Bent M.J., Brandes A.A., Rampling R., Kouwenhoven M.C., Kros J.M., Carpentier A.F., Clement P.M., Frenay M., Campone M., Baurain J.F., Armand J.P., Taphoorn M.J., Tosoni A., Kletzl H., Klughammer B., Lacombe D., Gorlia T. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009 Mar 10; 27 (8): 1268–74. doi: 10.1200/JCO.2008.17.5984.

22. Polgár C., Jánváry L., Major T., Somogyi A., Takácsi-Nagy Z., Fröhlich G., Fodor J. The role of high-dose-rate brachytherapy boost in breast-conserving therapy: Long-term results of the Hungarian National Institute of Oncology. Rep Pract Oncol Radiother. 2010 Feb 18; 15 (1):1–7. doi: 10.1016/j.rpor.2010.01.002.

23. Bahassi el M., Li Y.Q., Wise-Draper T.M., Deng L., Wang J., Darnell C.N., Wilson K.M., Wells S.I., Stambrook P.J., Rixe O. A patientderived somatic mutation in the epidermal growth factor receptor ligandbinding domain confers increased sensitivity to cetuximab in head and neck cancer. Eur J Cancer. 2013 Jul; 49 (10): 2345–55. doi: 10.1016/j.ejca.2013.03.005.

24. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20; 350 (21): 2129–39.

25. Soulieres D.S., Senze N.N., Vokes E.E., Hidalgo M., Agarwala S.S., Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004 Jan 1; 22 (1): 77–85.

26. Na I.I., Kang H.J., Cho S.Y., Koh J.S., Lee J.K., Lee B.C., Lee G.H., Lee Y.S., Yoo H.J., Ryoo B.Y., Yang S.H., Shim Y.S. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. Eur J Cancer. 2007 Feb; 43 (3): 520–6.

27. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., Riggs B.L., Horvath S., Liau L.M., Cavenee W.K., Rao P.N., Beroukhim R., Peck T.C., Lee J.C., Sellers W.R., Stokoe D., Prados M., Cloughesy T.F., Sawyers C.L., Mischel P.S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005 Nov 10; 353 (19): 2012–24.

28. Titova V.A., Avanesov A.M., Petrovskiy V.Yu. Feasibility of optimization of contact radiation therapy for cancer using individual fixing systems from the modern dental masses. Trudy NK RUDN MO RF, aprel’ 2014 g. [in Russian]

29. Dronova Е.L. Diagnostic imaging of oropharyngeal tumors. Siberian Journal of Oncology. 2010; 3: 63–64. [in Russian]

30. Ukpo O.C., Pritchett C.V., Lewis J.E., Weaver A.L., Smith D.I., Moore E.J. Human papillomavirus-associated oropharyngeal squamous cell carcinomas: primary tumor burden and survival in surgical patients. Ann Otol Rhinol Laryngol. 2009 May; 118 (5): 368–73.